Advertisement
AZN vs SNY
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZN is a Hold and SNY is a Hold.
AZN's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for AZN turned positive on October 15, 2026. Looking at past instances where AZN's MACD turned positive, the stock continued to rise in 30 of 43 cases over the following month. The odds of a continued upward trend are 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 34 of 53 cases where AZN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 64%.
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on AZN as a result. In 45 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 57%.
AZN moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +6.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where AZN advanced for three days, in 191 of 338 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
AZN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day moving average for AZN crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.
The 50-day moving average for AZN moved below the 200-day moving average on September 18, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.123) is normal, around the industry mean (19.199). P/E Ratio (24.873) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (1.168) is also within normal values, averaging (5.738). Dividend Yield (0.019) settles around the average of (0.025) among similar stocks. P/S Ratio (4.148) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 18 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. AZN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 52 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
SNY's RSI Oscillator ascending out of oversold territory
The RSI Indicator for SNY moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 17 of the 27 cases the stock moved higher. This puts the odds of a move higher at 63%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 30 of 60 cases where SNY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 50%.
The Moving Average Convergence Divergence (MACD) for SNY just turned positive on October 15, 2026. Looking at past instances where SNY's MACD turned positive, the stock continued to rise in 27 of 48 cases over the following month. The odds of a continued upward trend are 56%.
Following a +2.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNY advanced for three days, in 156 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 51%.
SNY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day moving average for SNY crossed bearishly below the 50-day moving average on September 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 47%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.
The Aroon Indicator for SNY entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.253) is normal, around the industry mean (19.199). P/E Ratio (22.411) is within average values for comparable stocks, (34.793). SNY's Projected Growth (PEG Ratio) (27.976) is very high in comparison to the industry average of (5.738). SNY has a moderately high Dividend Yield (0.059) as compared to the industry average of (0.025). P/S Ratio (1.829) is also within normal values, averaging (4.033).
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. SNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 94 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock worse than average.
AZN | SNY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 80 | 78 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 7 Undervalued | 43 Fair valued | |
PROFIT vs RISK RATING 1..100 | 18 | 94 | |
SMR RATING 1..100 | 44 | 81 | |
PRICE GROWTH RATING 1..100 | 43 | 71 | |
P/E GROWTH RATING 1..100 | 52 | 12 | |
SEASONALITY SCORE 1..100 | 24 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AZN's Valuation (7) in the Pharmaceuticals Major industry is somewhat better than the same rating for SNY (43). This means that AZN’s stock grew somewhat faster than SNY’s over the last 12 months.
AZN's Profit vs Risk Rating (18) in the Pharmaceuticals Major industry is significantly better than the same rating for SNY (94). This means that AZN’s stock grew significantly faster than SNY’s over the last 12 months.
AZN's SMR Rating (44) in the Pharmaceuticals Major industry is somewhat better than the same rating for SNY (81). This means that AZN’s stock grew somewhat faster than SNY’s over the last 12 months.
AZN's Price Growth Rating (43) in the Pharmaceuticals Major industry is in the same range as SNY (71). This means that AZN’s stock grew similarly to SNY’s over the last 12 months.
SNY's P/E Growth Rating (12) in the Pharmaceuticals Major industry is somewhat better than the same rating for AZN (52). This means that SNY’s stock grew somewhat faster than AZN’s over the last 12 months.
| AZN | SNY | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 63% |
| Stochastic ODDS (%) | 2 days ago 64% | 2 days ago 50% |
| Momentum ODDS (%) | 2 days ago 57% | N/A |
| MACD ODDS (%) | 2 days ago 70% | 2 days ago 56% |
| TrendWeek ODDS (%) | 2 days ago 55% | 2 days ago 53% |
| TrendMonth ODDS (%) | 2 days ago 56% | 2 days ago 47% |
| Advances ODDS (%) | 2 days ago 57% | 2 days ago 51% |
| Declines ODDS (%) | 4 days ago 46% | 4 days ago 52% |
| BollingerBands ODDS (%) | 2 days ago 62% | 2 days ago 54% |
| Aroon ODDS (%) | N/A | 2 days ago 51% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AZN’s FA Score shows that 2 FA rating(s) are green while SNY’s FA Score has 1 green FA rating(s).
- AZN’s FA Score: 2 green, 3 red.
- SNY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AZN’s TA Score shows that 6 TA indicator(s) are bullish while SNY’s TA Score has 5 bullish TA indicator(s).
- AZN’s TA Score: 6 bullish, 3 bearish.
- SNY’s TA Score: 5 bullish, 3 bearish.
Price Growth
AZN (@Pharmaceuticals: Major) experienced а +4.98% price change this week, while SNY (@Pharmaceuticals: Major) price change was +0.15% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.13%. For the same industry, the average monthly price growth was -3.71%, and the average quarterly price growth was +4.20%.
Reported Earning Dates
AZN is expected to report earnings on Oct 30, 2026.
SNY is expected to report earnings on Oct 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.13% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
SNY and
Correlation & Price change
A.I.dvisor indicates that over the last year, SNY has been loosely correlated with PFE. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if SNY jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To SNY | 1D Price Change % | ||
|---|---|---|---|---|
| SNY | 100% | +1.31% | ||
| PFE - SNY | 47% Loosely correlated | +0.79% | ||
| JNJ - SNY | 36% Loosely correlated | -0.25% | ||
| MRK - SNY | 35% Loosely correlated | -1.48% | ||
| AMGN - SNY | 35% Loosely correlated | +1.86% | ||
| GILD - SNY | 34% Loosely correlated | +2.49% | ||
More | ||||